We develop proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology and autoimmune diseases


10 March 2021

We signed strategy agreement with Tapemark, American manufacturer of transdermal systems

Tapemark a world-class leader in the development of complex transdermal drug delivery systems, has become a strategic partner of Biotts. Our ...


26 January 2021

How Biotts work during a pandemic

The pandemic has forced many companies to reorganise their working patterns. In the link below you can check the information on what has changed ...


27 October 2020

Forbes Poland about Biotts!

In latest article with @Forbespolska we’ve been discussing about our startup, investors, development plans and breakthrough MTC-Y technology. To ...


01 October 2020

We are the new InCredibles – mentoring program by Sebastian Kulczyk

We are the new InCredibles! Biotts as the winner of the Startup Challenge contest, organized as part of European Economic Congress/ European Tech ...



BIOTTS S.A. is a Polish biotechnological company that develops proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology, and autoimmune diseases. The team of Biotts technologists has developed a proprietary technology for obtaining a universal transdermal therapeutic system: MTC-Y. Thanks to the unique properties of the system, it is possible to increase the bioavailability of active substances by several times, allowing active substances to penetrate through skin barriers up to several centimetres, reaching soft tissues and bones. The unique transdermal MTC-Y system can be easily modified to achieve a targeted action in pathologically changed tissues. By increasing the bioavailability of the substance, it is possible to reduce the therapeutic dose, while maintaining the original effect and, at the same time, reducing the side effects. The unique transdermal Biotts system enables the transport of one to several active substances, thanks to which it is possible to design multi-component drugs. Through simple modifications of the system, it is also possible to design medicines with a modified release profile for the medicinal substance.

How it works transdermal Biotts technology:

With more than thirty years of experience, the Research and Development Team is able to effectively create proprietary medicines, solve complex technological problems and create unique solutions to help people all over the world.

BIOTTS S.A. also provides research and development services for pharmaceutical, biotechnological, cosmetic and chemical companies from all over the world.

We have provided the market with a wide variety of solutions, including: a non-aggregating nanocarrier used in the production of vitamin preparations, anti-allergic drugs, semi-solid forms of a drug with a deep penetration carrier, semi-solid forms of a drug accelerating tissue reconstruction, cosmetic products with increased bioavailability based on natural resources, medicinal gels, stabilised and naturally preserved omega acids, and functional food formulas.

Duńska 7 st.
54-427 Wrocław

Wrocław Technology Park
Omega Building
Duńska 7 street
54-424 Wrocław

Our clients